ALAMEDA, Calif., Nov. 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that Kevin Sullivan has tendered his resignation from the company's Board of Directors for personal health reasons, effective immediately.
"Kevin's contributions to Penumbra have been immeasurable," said Penumbra Chairman and CEO Adam Elsesser. "Going back to his commitment as an investor during the early days following Penumbra's founding and continuing with his service on the Board, Kevin's strategic thinking and understanding of how to scale a business and manage and motivate people is, without question, exceptional. He has been an incredible asset to the Penumbra Board of Directors. I will be forever thankful for Kevin's service to our company, and we will keep Kevin in our thoughts as he tends to his health with the support of his family and friends."
From 1987 until his retirement in 1999, Mr. Sullivan served as a senior human resources executive at a number of companies, including Wells Fargo and Company and Apple Computer, and as an Executive Consultant at Watson Wyatt Worldwide. Prior to that Mr. Sullivan held various personnel management positions of increasing responsibility at Digital Equipment Corporation.
About Penumbra Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.